Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been given a consensus rating of “Moderate Buy” by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.50.

Several research firms have commented on NRSN. Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a research report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price target for the company. D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, March 25th. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th.

NeuroSense Therapeutics Price Performance

Shares of NRSN stock opened at $0.76 on Friday. The stock’s 50-day moving average is $0.87 and its 200 day moving average is $0.98. NeuroSense Therapeutics has a 1-year low of $0.63 and a 1-year high of $2.60. The company has a market cap of $24.81 million, a P/E ratio of -1.41 and a beta of 1.70.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRSN. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics during the 4th quarter valued at about $77,000. Squarepoint Ops LLC grew its stake in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter valued at about $54,000. Finally, Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the 3rd quarter valued at approximately $26,000. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.